Type of cannabinoidergic drug
An endocannabinoid enhancer (eCBE ) is a type of cannabinoidergic [ 1] drug that enhances the activity of the endocannabinoid system by increasing extracellular concentrations of endocannabinoids .[ 2] [ 3] [ 4] [ 5] Examples of different types of eCBEs include fatty acid amide hydrolase (FAAH) inhibitors , monoacylglycerol lipase (MAGL) inhibitors , and endocannabinoid transporter (eCBT) inhibitors (or "endocannabinoid reuptake inhibitors " ("eCBRIs")).[ 2] [ 3] [ 4] [ 5] An example of an actual eCBE is AM404 , the active metabolite of the analgesic paracetamol (acetaminophen; Tylenol) and a dual FAAH inhibitor and eCBRI.[ 6] [ 7] [ 8]
^ George I. Papakostas; Maurizio Fava (2010). Pharmacotherapy for Depression and Treatment-resistant Depression . World Scientific. pp. 323–. ISBN 978-981-4287-59-3 .
^ a b Bambico, Francis Rodriguez; Gobbi, Gabriella (2008). "The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets". Expert Opinion on Therapeutic Targets . 12 (11): 1347–1366. doi :10.1517/14728222.12.11.1347 . ISSN 1472-8222 . PMID 18851692 . S2CID 86111417 .
^ a b Di Marzo, Vincenzo (2008). "Targeting the endocannabinoid system: to enhance or reduce?". Nature Reviews Drug Discovery . 7 (5): 438–455. doi :10.1038/nrd2553 . ISSN 1474-1776 . PMID 18446159 . S2CID 21081378 .
^ a b Saito, Viviane M.; Wotjak, Carsten T.; Moreira, Fabrício A. (2010). "Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?" . Rev Bras Psiquiatr . 32 (1): 57–514. doi :10.1590/S1516-44462010000500004 . ISSN 1516-4446 . PMID 20512266 .
^ a b Micale, Vincenzo; Di Marzo, Vincenzo; Sulcova, Alexandra; Wotjak, Carsten T.; Drago, Filippo (2013). "Endocannabinoid system and mood disorders: Priming a target for new therapies". Pharmacology & Therapeutics . 138 (1): 18–37. doi :10.1016/j.pharmthera.2012.12.002 . ISSN 0163-7258 . PMID 23261685 .
^ Giuffrida A, Beltramo M, Piomelli D (2001). "Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology". J. Pharmacol. Exp. Ther . 298 (1): 7–14. PMID 11408519 .
^ Anderson BJ (2008). "Paracetamol (Acetaminophen): mechanisms of action" . Paediatr Anaesth . 18 (10): 915–21. doi :10.1111/j.1460-9592.2008.02764.x . PMID 18811827 . S2CID 17115356 .
^ Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S (2006). "Paracetamol: new vistas of an old drug" . CNS Drug Rev . 12 (3–4): 250–75. doi :10.1111/j.1527-3458.2006.00250.x . PMC 6506194 . PMID 17227290 .